SavedAdd your journal

Journals / Zeynep Kamil Tıp Bülteni / 2015 / Cilt: 46 - Sayı: 4

C-KIT Ekspresyonunun Değerlendirilmesi Immunohistochemical Evaluation of C-KIT Expression in Uterine Carcinosarcomas

KTB Uterin Karsinosarkomlarda İmmunohistokimyasal Olarak C-KIT Ekspresyonunun Değerlendirilmesi

Ecmel Işık KAYGUSUZ
Pages
93–97
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The purpose of the present study was to assess c-kit expression in the carcinomatous and sarcomatous component of carcinosarcoma and to identify if KIT represents a therapeutic target for treatment of this neoplasm.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Carcinosarcoma is a very aggressive neoplasm.
📊
Key Findings & Data:Consequently, c-kit expression may have significant clinical implications for this tumor.
💡
Conclusion & Impact:The purpose of the present study was to assess c-kit expression in the carcinomatous and sarcomatous component of carcinosarcoma and to identify if KIT represents a therapeutic target for treatment of this neoplasm.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Carcinosarcoma is a very aggressive neoplasm. The use of tyrosine kinase inhibitors has resulted in successful treatment of KIT-positi- ve neoplasms. Consequently, c-kit expression may have significant clinical implications for this tumor. The purpose of the present study was to assess c-kit expression in the carcinomatous and sarcomatous component of carcinosarcoma and to identify if KIT represents a therapeutic target for treatment of this neoplasm.

Özet

Amaç: Karsinosarkom oldukça agresif bir neop- lazmdır. KIT-pozitif neoplazmlarda tirozin kinaz in- hibitörleri tedavide başarılı sonuçlar vermektedir. Bu nedenle, bu tümörlerde c-kit ekspresyonu klinik açıdan önemli olabilir. Bu çalışmanın amacı, kar- sinosarkomun karsinomatöz ve sarkomatöz kompo- nenetlerinde c-kit ekspresyonunu incelemek ve bu neoplazmlarda KIT’in terapötik bir hedef olarak kullanılabilirliğini saptamaktır.

🔖

Cite This Article

KAYGUSUZ, E. I. (2015). C-KIT Ekspresyonunun Değerlendirilmesi Immunohistochemical Evaluation of C-KIT Expression in Uterine Carcinosarcomas. Zeynep Kamil Tıp Bülteni, Cilt: 46 - Sayı: 4, 93–97. https://ajindex.com/articles/335280

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, et al. Human proto-oncogene kit, a new cell sur- face-receptor tyrosine kinase for unidentified ligand. EMBO J 1987;6:3341 – 51
  2. Williams DE, Eisenman J, Baird A, Rauch C, Van Ness K, March CJ, et al. Identification of a ligand for the c-kit proto-on- cogene. Cell 1990;63:167 – 74. 3. d’Auriol L, Mattei MG, Andre C, Galibert F. Localization of the human c-kit protooncogene on the q11–q12 region of chro- mosome 4. Hum Genet 1988;78:374 – 6
  3. Nakata Y, Kimura A, Katoh O, Kawaishi K, Hyodo H, Abe K, et al. C-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 1995;91:6610 – 30
  4. Dudani S, Kalhan S, Sharma S, Gupta A. Gastrointestinal stromal tumours (GIST)-pathology and clinical applications of recent molecular advences-A perspective review. Çağdaş Tıp Dergisi 2014;4:85-90
  5. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stroma. Cancer Res 2001;61(22):8118 – 21
  6. Demetri GD. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinibe mesylate (STI571) Eur J Cancer 2002;38 (Suppl 5):52–59
  7. Druker BJ, Sawyers CL., Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chro- mosome N Engl J Med 2001;344:1038–42
  8. DeMatteo RP. The GIST of targeted cancer therapy: a tumor gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular nhibitor (STI571) Ann Surg Oncol 2002;9:831–3
  9. Demetri GD. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol 2001;28 (Suppl 17):19–26
  10. Heinrich MC., Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT ac- tivation and cytogenetic alterations. Hum Pathol 2002;33:484 – 95
  11. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhi- bition of KIT tyrosine kinase activity: a novel molecular ap- proach to treatment of KIT-positive malignancies J Clin Oncol 2002;20:1692–703
  12. Elmore LW, Domson K, Moore JR, Kornstein M, Burks RT. Expression of c-kit (CD117) in benign and malignant human endometrial epithelium. Arch Pathol Lab Med 2001;125:146– 51
  13. Scobie JV, Acs G